Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
about
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsErythropoietin or darbepoetin for patients with cancerBiosimilars: potential implications for cliniciansCurrent status of biosimilars in the treatment of inflammatory bowel diseasesPhysiology and pharmacology of erythropoietinReview article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesThe Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesThe approval process for biosimilar erythropoiesis-stimulating agentsEtanercept biosimilarsPotential impact of subsequent entry biologics in nephrology practice in Canada.Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Biosimilars: the debate continues.Regulatory and clinical considerations for biosimilar oncology drugsThe economic pressures for biosimilar drug use in cancer medicineEffects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Colony-stimulating factors for febrile neutropenia during cancer therapy.Drug development in inflammatory bowel disease: the role of the FDA.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Current state and perspectives on erythropoietin production.Subsequent entry biologics/biosimilars: a viewpoint from Canada.Epoetin biosimilars in Europe: five years on.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin.Peginesatide for the treatment of renal disease-induced anemia.Detection of peptidic erythropoiesis-stimulating agents in sport.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation.Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.Multivariate statistics for the differentiation of erythropoietin preparations based on intact glycoforms determined by CE-MS.Expression of functionally active sialylated human erythropoietin in plantsEfficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study.ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).Biosimilar rhG-CSFs: how similar are they?The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.Mass spectrometric characterisation of darbepoetin alfa biosimilars with C-terminal arginine residues.Biosimilar medical products - licensing, pharmacovigilance and interchangeability.Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach
P2860
Q24198118-E4C77D23-B57B-4823-893C-18EA8ECDF55EQ24202335-05B16BB1-662F-4257-ABF5-788B8F80DB87Q26744332-A71EFD24-5C0A-475A-AF77-26D10B0FEFC8Q26765350-36BE3C2F-70BA-443D-B2B2-5A683AE4AA94Q26866945-AD4D349E-C0D9-488F-9162-F6DBB2EA1820Q27013577-432607F2-A6E7-4D99-8ECA-741CB86C97CBQ33665611-63C75FCB-FB4F-4192-AAD1-3188CDFB8D41Q34124734-0CC07D35-C1A7-4002-AB9B-F14872871AAEQ35020358-C66E853A-A23E-496D-AFF1-CE6C41303BAFQ35146196-566BCE50-920F-4D41-B195-F880DA5FC802Q35162053-D54E8394-E33C-48B4-898E-2B711B2A0A77Q35432608-82F8DB4F-13F5-4D19-9DB2-939967720C06Q35505833-3CDF0032-0912-462C-A8E6-941A38CFC197Q35795204-39C19F1B-5F4C-4BDC-9F34-4E1353694727Q35858979-D70B30A9-007B-47A1-9CD6-DDAE41C6ED90Q37626772-6325726B-BA0A-40BC-BB60-6DA3D0E98595Q37864253-786450EE-8397-456D-BD02-D6627A2814AFQ37999380-BBBE1E47-6485-4697-91DD-F4196493BACEQ38006021-1E5AA057-4AB2-44DB-9EF9-F9CA29F0C8C3Q38028315-4BEE40BE-9194-49A7-ABA1-A2DED1B838B7Q38038103-08972EF8-6355-47D3-B22F-7254E470D35AQ38067654-DDE9AAB7-BF6C-433F-9825-EEC6AE729C97Q38075798-D413586E-8EFE-4A1E-9089-14E17263C497Q38083095-D6650ED0-AB4C-4DD7-BF89-7BEC550C6895Q38090725-3628E60F-1069-407E-994F-D156218F030BQ38200014-FF2FD2A0-DAD9-4D5B-8CAC-010B983A5E4AQ38708927-1989AC4D-C15E-498D-B0E8-1AF70750E9D6Q38763700-D5279E92-BA1D-4EA1-B3E7-410380827C79Q38974661-1723489E-6F1C-4D21-AE09-1BAA5CD22215Q39138759-4364C5A8-6C1C-407C-B18D-4AB0892F3E6CQ39141802-9AD5139E-92DE-4059-B1B7-EC5745A270D0Q39376945-8E15DCE0-BC87-4F14-8055-D1745F933D7FQ42229402-7575DC68-8519-4FA6-B72A-EDC18214E6FFQ42803012-EE610ED4-53FB-457D-A8F6-B440983D4242Q44633613-D3A6843B-1C64-4B3E-9B46-EEC97FA4EDE9Q45788056-71EFB059-A8C6-4540-8A1C-93E86418C1FAQ47760510-4BCAA8E0-0B4E-45B2-BD90-0A27B4C0B589Q51427388-B5921A20-960E-4B24-9A2D-F85E8AA53D24Q52988594-B387BF08-1B85-4BC2-9BFC-5530A0D86AA8Q57191817-475484D7-D63B-4564-B00F-F5314EC4A8A0
P2860
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@ast
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@en
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@nl
type
label
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@ast
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@en
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@nl
prefLabel
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@ast
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@en
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@nl
P2860
P356
P1476
Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
@en
P2093
Wolfgang Jelkmann
P2860
P304
P356
10.1002/AJH.21805
P577
2010-10-01T00:00:00Z